/ 2 items

#BIOA↓

BIOA/ 01/27/2026 · 7:20 AM

Piper Sandler Starts Coverage on BioAge Labs With Buy Rating and $73 Target

Piper Sandler initiates coverage of BioAge Labs with an Overweight rating, highlighting strong early data for its lead drug BGE-102 and key upcoming catalysts.

BIOA/ 10/22/2025 · 6:40 AM

Citi Upgrades BioAge Labs Stock on Promising Obesity Drug Potential

Citi analyst upgrades BioAge Labs to Buy with $10 price target, citing BGE-102 obesity drug as potentially game-changing treatment option.